Mereo BioPharma Group plc
MREOHealthcare|Biotechnology|GB
$0.28
+0.00 (+0.93%)
DCF Value
$0.26
Tangible Book / Share
$0.18
Cash / Share
$0.19
Clinical Trials (51)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05125809 Setrusumab vs Placebo for Osteogenesis Imperfecta | Osteogenesis Imperfecta | P2P3 | Active | 183 | RCT, Double-blind | Setrusumab |
| NCT05715216 EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | P2 | Active | 23 | Open-label | Nivolumab, Etigilimab |
| NCT03986086 MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation | Hematologic Malignancy | P1P2 | Withdrawn | — | RCT, Double-blind | MPH966, Placebo |
| NCT01116440 A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis | Pelvic Pain Associated With Refractory Endometriosis | P2 | Terminated | 27 | RCT, Double-blind | BGS649, Placebo |
| NCT01406548 Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density | Osteopenia, Osteoporosis | P2 | Completed | 44 | RCT, Double-blind | BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804 |
| NCT04761198 A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | Solid Tumor, Adult, Advanced Solid Tumor | P1P2 | Completed | 76 | Open-label | Etigilimab, Nivolumab |
| NCT02259582 A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | P2 | Completed | 82 | RCT, Double-blind | Pemetrexed, Carboplatin, demcizumab |
| NCT02289898 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer | P2 | Completed | 207 | RCT, Double-blind | Demcizumab, Abraxane®, gemcitabine, Placebo |
| NCT01406977 Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) | Hypophosphatasia | P2 | Completed | 8 | Open-label | BPS804 |
| NCT01806610 Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease | Chronic-kidney Disease Stage 5D on Stable Hemodialysis | P2 | Withdrawn | — | RCT, Double-blind | BPS804, Placebo |
| NCT03216486 An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta | Osteogenesis Imperfecta | P2 | Withdrawn | — | Open-label | BPS804 |
| NCT02908074 A 6 Month Safety Extension Study of MBGS205 | Hypogonadotropic Hypogonadism | P2 | Completed | 143 | RCT, Double-blind | BGS649 |
| NCT01859741 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy | Stage IV Small Cell Lung Cancer | P1P2 | Terminated | 172 | RCT, Double-blind | OMP-59R5, Etoposide, Placebo, Cisplatin or Carboplatin |
| NCT03118570 A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804 | Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III | P2 | Completed | 112 | RCT, Double-blind | setrusumab, zoledronic acid (optional) |
| NCT01200862 Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men | Obese Hypogonadotropic Hypogonadism | P2 | Terminated | 29 | RCT, Double-blind | Investigational new drug company code: BGS649, Placebo |
| NCT01332097 Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation | Chronic Obstructive Pulmonary Disease | P2 | Completed | 183 | RCT, Double-blind | BCT197, Prednisone placebo, BCT197 placebo, Prednisone |
| NCT03636347 A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | Alpha 1-Antitrypsin Deficiency, Emphysema | P2 | Completed | 99 | RCT, Double-blind | Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2 |
| NCT02730169 Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism | Hypogonadotropic Hypogonadism | P2 | Completed | 271 | RCT, Double-blind | BGS649, Placebo |
| NCT01190475 BGS649 Monotherapy in Moderate to Severe Endometriosis Patients | Endometriosis | P2 | Completed | 6 | RCT, Double-blind | Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study |
| NCT02700919 Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease | Pulmonary Disease, Chronic Obstructive | P2 | Completed | 282 | RCT, Double-blind | BCT197, Placebo |
| NCT04539795 COVID-19 Study of Safety and Tolerability of Alvelestat | Covid19 | P1P2 | Completed | 15 | RCT, Double-blind | Alvelestat, Placebo |
| NCT01336959 Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery | Acute Kidney Injury | P2 | Terminated | 91 | RCT, Double-blind | BCT197 Part A, Placebo, BCT197 Part B |
| NCT03679598 Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency | Alpha-1 Antitrypsin Deficiency (AATD), Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations | P2 | Completed | 63 | RCT, Double-blind | Alvelestat (MPH966) |
| NCT05312697 Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta | Osteogenesis Imperfecta | P2 | Terminated | 2 | RCT, Open-label | Setrusumab |
| NCT01647828 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Stage IV Pancreatic Cancer | P1P2 | Completed | 217 | RCT, Double-blind | OMP-59R5, Gemcitabine, Placebo, Nab-Paclitaxel |
| NCT02722954 A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | P1 | Completed | 29 | Open-label | Demcizumab, Pembrolizumab |
| NCT01703572 A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | Relapsed or Refractory Lymphoid Malignancies | P1 | Completed | 24 | Open-label | OMP-52M51 |
| NCT02069145 Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | Hepatocellular Cancer, Liver Cancer | P1 | Completed | 10 | Open-label | OMP-54F28 with Sorafenib |
| NCT02482441 A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 | Advanced Relapsed Tumors, Refractory Solid Tumors | P1 | Completed | 50 | Open-label | OMP-131R10, FOLFIRI |
| NCT01778439 A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors | Relapsed or Refractory Solid Tumors | P1 | Completed | 48 | Open-label | OMP-52M51 |
| NCT01277146 A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors | Solid Tumors | P1 | Completed | 42 | Open-label | OMP-59R5 |
| NCT02005315 A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | Pancreatic Cancer, Stage IV Pancreatic Cancer | P1 | Completed | 30 | Open-label | Vantictumab, Nab-Paclitaxel, Gemcitabine |
| NCT02926326 The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers | Interaction | P1 | Completed | 16 | Open-label | BCT197, Azithromycin |
| NCT02298387 A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors | Advanced Solid Tumor Malignancies | P1 | Completed | 71 | Open-label | OMP-305B83 |
| NCT00744562 A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors | Solid Tumors | P1 | Completed | 42 | Open-label | OMP-21M18 |
| NCT01957007 A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC | Solid Tumors | P1 | Completed | 34 | Open-label | Docetaxel, vantictumab |
| NCT02092363 Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | Ovarian Cancer | P1 | Completed | 37 | Open-label | OMP-54F28, Paclitaxel and Carboplatin |
| NCT03031691 A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Completed | 7 | Open-label | brontictuzumab, trifluridine/tipiracil |
| NCT01189942 A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | Colorectal Cancer | P1 | Completed | 18 | Open-label | OMP-21M18 |
| NCT01189968 A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | P1 | Completed | 50 | Open-label | Demcizumab |
| NCT03035253 A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Terminated | 16 | Open-label | OMP-305B83, FOLFIRI, FOLFOX |
| NCT02050178 Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | Pancreatic Cancer, Stage IV Pancreatic Cancer | P1 | Completed | 26 | Open-label | OMP-54F28, Nab-Paclitaxel and Gemcitabine |
| NCT03295942 A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors | Locally Advanced Malignant Neoplasm, Metastatic Cancer | P1 | Terminated | 24 | Open-label | OMP-336B11 |
| NCT03498170 The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants | Interaction | P1 | Completed | 16 | Open-label | BCT197, Itraconazole 200 mg |
| NCT01973309 A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer | Metastatic Breast Cancer | P1 | Completed | 37 | Open-label | Vantictumab combined with paclitaxel |
| NCT01345201 A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors | Solid Tumors | P1 | Completed | 35 | Open-label | OMP-18R5 |
| NCT01189929 A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | Pancreatic Cancer | P1 | Completed | 57 | Open-label | Demcizumab, Abraxane®, Gemcitabine |
| NCT01608867 A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors | Solid Tumors | P1 | Completed | 26 | Open-label | OMP-54F28 |
| NCT03119428 A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors | Locally Advanced Cancer, Metastatic Cancer | P1 | Terminated | 33 | Open-label | OMP-313M32, Nivolumab |
| NCT01952249 A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Primary Peritoneal Carcinoma | P1 | Terminated | 20 | Open-label | Demcizumab, Taxol |
| NCT03030287 A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | Cancer Ovaries, Cancer Peritoneal | P1 | Completed | 44 | Open-label | OMP-305B83, Paclitaxel |